Login to Your Account



Surprise phase III result bonks Intra-Cellular stock

By Michael Fitzhugh
Staff Writer

Thursday, September 29, 2016

An elevated placebo response matching the efficacy of experimental schizophrenia drug ITI-007 in a phase III trial sent shares of its developer, Intra-Cellular Therapies Inc., down 63.6 percent Thursday.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription